Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 571天前
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 390天前
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 424天前
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1152天前
DAX Extending Recent Weakness

DAX Extending Recent Weakness

German stocks are down in negative territory on Tuesday, extending losses from the previous session, due to geopolitical concerns and uncertainty about tariffs.
RTTNews | 1小時11分鐘前
Sensex, Nifty Tumble On Tariff Worries

Sensex, Nifty Tumble On Tariff Worries

Indian shares tumbled on Tuesday after the Trump administration officially issued a notice regarding the imposition of an additional 25 percent tariffs on Indian imports, with the punitive duties set to kick in at 12:01 am (EST) on August 27.
RTTNews | 1小時16分鐘前
French Consumer Sentiment Weakest Since 2023

French Consumer Sentiment Weakest Since 2023

France's consumer confidence weakened to the lowest level since October 2023 largely due to the weaker outlook for standard of living and the fall in saving intentions. The consumer sentiment index edged down to 87 in August from 88 in July. This was the lowest reading since October 2023 and remained below its long-term average of 100.
RTTNews | 2小時24分鐘前